<DOC>
	<DOCNO>NCT00041730</DOCNO>
	<brief_summary>The purpose study evaluate ability patient treat Rituxan® plus FavId™ GM-CSF mount immune response ( humoral and/or cellular ) KLH idiotype .</brief_summary>
	<brief_title>Rituxan Plus FavId ( Idiotype Vaccine ) Low-grade Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>The purpose study evaluate ability patient treat Rituxan® plus FavId™ GM-CSF mount immune response ( humoral and/or cellular ) KLH idiotype . Secondary objective determination overall objective response rate , duration response time progression . B-cell malignancy express unique antigen , immunoglobulin idiotype ( Id ) , surface . Each B-cell harbor unique genetic sequence use production unique Id protein . No normal B-cells posse Id cell surface . Hence , Id protein serve ideal target individualize active immune therapy NHL . Many antigen express tumor ( include Id ) weak immunogen . To augment immune response Id , Id protein must chemically couple strongly immunogenic protein . keyhole limpet hemocyanin ( KLH ) commonly use protein carrier capable augment body 's immune reaction Id protein . For vaccine produce primarily antibody response , concern combine immunotherapy Rituxan® , produce rapid sustain ( 6 9 month post-treatment 83 % patient ) depletion circulate tissue-based B-cells , would blunt antibody response . For vaccine induce strong T-cell response like Id-KLH plus GM-CSF , evidence mouse deplete host B-cells could actually increase T-cell response vaccine . GM-CSF hematopoietic growth factor stimulate T-cell proliferation . T-cell response patient 's Idiotype KLH measure trial .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Immunoglobulin Idiotypes</mesh_term>
	<criteria>Inclusion Criteria 18 year age old Patients treatment naive OR Relapsed refractory follow chemotherapy OR Relapsed follow prior response Rituxan ( R ) Note : Rituxan ( R ) may give secondline therapy follow initial response chemotherapy combination chemotherapy initial therapy disease . Tumor accessible biopsy previously exist recent biopsy material Measurable disease node biopsy Histologically confirm grade 1 2 follicular Bcell lymphoma ( WHO classification ) Performance status ( ECOG ) 0 , 1 2 Absolute Granulocyte count &gt; 1,000/mm3 Platelets &gt; 100,000/mm3 Total Bilirubin &lt; 2 mg/dL AST ALT &lt; 2x Upper Limit Normal Creatinine &lt; 1.5 mg/dL Exclusion Criteria Patients refractory Rituxan ( R ) Note : Patients attain CR PR consider refractory More 2 prior treatment regimen ( e.g . CHOP plus Rituxan ( R ) one treatment regimen ; CHOP follow Rituxan ( R ) initial relapse equal two treatment regimen ) Treatment w/Fludarabine within 9 month study entry Patients &gt; 5,000 lymphocyte Prior tumorspecific idiotype immunotherapy use identical idiotype ( patient whose idiotype change eligible retreatment new idiotype ) Concurrent immunosuppressive therapy ( highdose steroid ; ect . ) Known history CNS lymphoma meningeal lymphomatosis HIV positive Serious nonmalignant disease ( e.g. , psychiatric disorder , compromise pulmonary function ( e.g . active asthma , COPD , pneumonitis , bronchiolitis obliterans ) , congestive heart failure , active uncontrolled bacterial , viral fungal infection ) , condition , opinion investigator would compromise protocol objective Prior malignancy ( exclude nonmelanoma carcinomas skin situ cervical carcinoma ) unless remission &gt; 2 year Treatment investigational drug within 8 week prior study entry Pregnant nursing woman NOTE : Women childbearing potential advise avoid become pregnant receiving study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2004</verification_date>
	<keyword>lymphoma</keyword>
	<keyword>vaccine</keyword>
	<keyword>idiotype</keyword>
	<keyword>KLH</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>FavId</keyword>
</DOC>